Last reviewed · How we verify
MTX-hold
MTX-hold is a methotrexate dosing strategy or formulation designed to optimize therapeutic efficacy while managing toxicity in autoimmune or oncologic conditions.
At a glance
| Generic name | MTX-hold |
|---|---|
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism is unclear from available public data, but 'MTX-hold' likely refers to a modified methotrexate administration protocol or delivery system under investigation at Seoul National University Hospital. Methotrexate is a folate antagonist and antimetabolite that inhibits dihydrofolate reductase, suppressing cell proliferation and immune responses. The 'hold' designation may indicate a novel dosing schedule, formulation, or combination strategy.
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia (PHASE3)
- One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis. (PHASE3)
- MTX Hold During Covid-19 Booster (PHASE3)
- MTX Discontinuation and Vaccine Response (PHASE4)
- 2-week dc of MTX and Influenza Vaccination in RA (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MTX-hold CI brief — competitive landscape report
- MTX-hold updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI